首页ALMKT • EPA
Mauna Kea Technologies SA
€0.19
1月30日, GMT+1 03:01:22 · EUR · EPA · 免责声明
股票在FR上市的证券
昨日收盘价
€0.19
当日价格范围
€0.18 - €0.19
年度波幅
€0.16 - €0.53
市值
1200.40万 EUR
平均交易量
12.18万
市盈率
-
股息率
-
主要交易所
EPA
市场资讯
财务信息
损益表
收入
净收入
(EUR)2024年6月年同比变化
收入
213.45万-40.22%
经营支出
350.55万-5.78%
净收入
-234.30万-267.42%
净利润率
-109.77-380.03%
每股收益
息税折旧摊销前利润
-176.30万-559.07%
有效税率
总资产
负债总额
(EUR)2024年6月年同比变化
现金及短期投资
381.70万-39.56%
总资产
1814.60万-25.14%
负债总额
3849.00万-5.23%
权益总额
-2034.40万
发行在外的股份
6461.75万
市净率
-0.60
资产回报率
-25.45%
资本回报率
-56.78%
现金净变动
(EUR)2024年6月年同比变化
净收入
-234.30万-267.42%
来自运营的现金
-190.20万-233.29%
投资现金
3.65万183.91%
融资现金
-22.65万-218.90%
现金净变动
-208.55万-232.96%
自由现金流
-80.29万-487.16%
简介
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts. The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues. Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time. Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
成立时间
2000
员工数量
65
一探究竟
用户还搜索了
搜索
清除搜索内容
关闭搜索框
Google 应用
主菜单